MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
In preclinical studies, MF59 adjuvant offered improved protection against influenza virus challenge and significantly reduced the viral load in the lungs of challenged mice. In humans, MF59 is a safe and potent vaccine adjuvant that has been licensed in more than 20 countries (Fluad [Novartis Vaccines and Diagnostics Inc., MA, USA]). The safety profile of an MF59-adjuvanted vaccine is well established through a large safety database. MF59 adjuvant has had a significant impact on the immunogenicity of influenza vaccines in the elderly and in adults who are chronically ill. MF59 has also been shown to have a significant impact on the immunogenicity of pandemic influenza vaccines. MF59 allows for broader cross-reactivity against viral strains not included in the vaccine. MF59 has been shown to be more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types.
O'Hagan
Derek T
DT
Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy. derek.ohagan@novartis.com
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D009975:Orthomyxoviridae / Q000276:immunology*; D011136:Polysorbates / Q000009:adverse effects / Q000627:therapeutic use*; D013185:Squalene / Q000009:adverse effects / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene